In conclusion, our study demonstrated the significance of using the ultra-sensitive ddPCR platform for the dynamic assessment of tissue and plasma EGFR mutation status at baseline and disease progression in EGFR mutant NSCLC treated with EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.